88 related articles for article (PubMed ID: 17652831)
1. Endothelin receptor antagonist CPU0213 suppresses ventricular fibrillation in L-thyroxin induced cardiomyopathy.
Feng Y; Dai DZ; Na T; Cui B; Wang T; Zhang Y; Dai Y
Pharmacol Rep; 2007; 59(3):306-14. PubMed ID: 17652831
[TBL] [Abstract][Full Text] [Related]
2. Downregulated FKBP12.6 expression and upregulated endothelin signaling contribute to elevated diastolic calcium and arrhythmogenesis in rat cardiomyopathy produced by l-thyroxin.
Zhang Y; Huang ZJ; Dai DZ; Feng Y; Na T; Tang XY; Dai Y
Int J Cardiol; 2008 Nov; 130(3):463-71. PubMed ID: 18684528
[TBL] [Abstract][Full Text] [Related]
3. A novel endothelin receptor antagonist CPU0213 improves diabetic cardiac insufficiency attributed to up-regulation of the expression of FKBP12.6, SERCA2a, and PLB in rats.
Qi MY; Xia HJ; Dai DZ; Dai Y
J Cardiovasc Pharmacol; 2006 Jun; 47(6):729-35. PubMed ID: 16810072
[TBL] [Abstract][Full Text] [Related]
4. Down-regulation of FKBP12.6 and SERCA2a contributes to acute heart failure in septic shock and is related to an up-regulated endothelin signalling pathway.
He HB; Yu F; Dai DZ; Dai Y
J Pharm Pharmacol; 2007 Jul; 59(7):977-84. PubMed ID: 17637193
[TBL] [Abstract][Full Text] [Related]
5. Abrupt changes in FKBP12.6 and SERCA2a expression contribute to sudden occurrence of ventricular fibrillation on reperfusion and are prevented by CPU86017.
Na T; Huang ZJ; Dai DZ; Zhang Y; Dai Y
Acta Pharmacol Sin; 2007 Jun; 28(6):773-82. PubMed ID: 17506935
[TBL] [Abstract][Full Text] [Related]
6. Reversal of isoproterenol-induced downregulation of phospholamban and FKBP12.6 by CPU0213-mediated antagonism of endothelin receptors.
Feng Y; Tang XY; Dai DZ; Dai Y
Acta Pharmacol Sin; 2007 Nov; 28(11):1746-54. PubMed ID: 17959025
[TBL] [Abstract][Full Text] [Related]
7. CPU0213, a novel endothelin receptor antagonist, suppresses the upregulation of matrix metalloproteinases and connexin 43 in hyperthyroid myocardium.
Tang XY; Liu Q; Dai DZ; Dai Y
Pharmacol Rep; 2008; 60(4):524-31. PubMed ID: 18799821
[TBL] [Abstract][Full Text] [Related]
8. Up-regulated inflammatory factors endothelin, NFkappaB, TNFalpha and iNOS involved in exaggerated cardiac arrhythmias in l-thyroxine-induced cardiomyopathy are suppressed by darusentan in rats.
Xia HJ; Dai DZ; Dai Y
Life Sci; 2006 Oct; 79(19):1812-9. PubMed ID: 16822527
[TBL] [Abstract][Full Text] [Related]
9. Protective effect of the endothelin antagonist CPU0213 against isoprenaline-induced heart failure by suppressing abnormal expression of leptin, calcineurin and SERCA2a in rats.
Xu M; Ji H; Dai DZ; Tang XY; Dai Y
J Pharm Pharmacol; 2008 Jun; 60(6):739-45. PubMed ID: 18498710
[TBL] [Abstract][Full Text] [Related]
10. Inflammatory factors that contribute to upregulation of ERG and cardiac arrhythmias are suppressed by CPU86017, a class III antiarrhythmic agent.
Du RH; Yi HW; Dai DZ; Tang WH; Dai Y
J Pharm Pharmacol; 2008 Aug; 60(8):1089-95. PubMed ID: 18644201
[TBL] [Abstract][Full Text] [Related]
11. Endothelin receptor antagonist CPU0213 and vitamin E reverse downregulation of FKBP12.6 and SERCA2a: a role of hyperphosphorylation of PKCepsilon.
Li N; Jia N; Dai DZ; Dai Y
Eur J Pharmacol; 2008 Sep; 591(1-3):211-8. PubMed ID: 18611397
[TBL] [Abstract][Full Text] [Related]
12. Upregulation of leptin pathway correlates with abnormal expression of SERCA2a, phospholamban and the endothelin pathway in heart failure and reversal by CPU86017.
Na T; Dai DZ; Tang XY; Dai Y
Naunyn Schmiedebergs Arch Pharmacol; 2007 Mar; 375(1):39-49. PubMed ID: 17287947
[TBL] [Abstract][Full Text] [Related]
13. Upregulation of SERCA2a following short-term ACE inhibition (by enalaprilat) alters contractile performance and arrhythmogenicity of healthy myocardium in rat.
Matus M; Kucerova D; Kruzliak P; Adameova A; Doka G; Turcekova K; Kmecova J; Kyselovic J; Krenek P; Kirchhefer U; Mueller FU; Boknik P; Klimas J
Mol Cell Biochem; 2015 May; 403(1-2):199-208. PubMed ID: 25663023
[TBL] [Abstract][Full Text] [Related]
14. The endothelin receptor antagonist CPU0213 is more effective than aminoguanidine to attenuate isoproterenol-induced vascular abnormality by suppressing overexpression of NADPH oxidase [correction of oxidas], ETA, ETB, and MMP9 in the vasculature.
Xu J; Li N; Dai DZ; Yu F; Dai Y
J Cardiovasc Pharmacol; 2008 Jul; 52(1):42-8. PubMed ID: 18594475
[TBL] [Abstract][Full Text] [Related]
15. Effect of the endothelin receptor antagonist CPU0213, and its modulation by rifampin, on cardiac and vascular tissue following chronic isoproterenol treatment.
Luo L; Dai DZ; Dai Y
Clin Exp Pharmacol Physiol; 2008 Jul; 35(7):757-65. PubMed ID: 18215179
[TBL] [Abstract][Full Text] [Related]
16. The correlation between angiogenesis and abnormal expression of SERCA2a, phospholamban and the endothelin pathway in heart failure, and improvement by puerarin.
He H; Shi M; Yang J; Zeng X; Qiao H; Wu L; Li L
Phytother Res; 2008 Jul; 22(7):948-56. PubMed ID: 18389490
[TBL] [Abstract][Full Text] [Related]
17. Total triterpene acids, active ingredients from Fructus Corni, attenuate diabetic cardiomyopathy by normalizing ET pathway and expression of FKBP12.6 and SERCA2a in streptozotocin-rats.
Qi MY; Liu HR; Dai DZ; Li N; Dai Y
J Pharm Pharmacol; 2008 Dec; 60(12):1687-94. PubMed ID: 19000375
[TBL] [Abstract][Full Text] [Related]
18. Induced ion currents and the endothelin pathway as targets for anti-arrhythmic agents.
Dai DZ; Dai Y
Curr Opin Investig Drugs; 2008 Sep; 9(9):1001-8. PubMed ID: 18729007
[TBL] [Abstract][Full Text] [Related]
19. Isoproterenol disperses distribution of NADPH oxidase, MMP-9, and pPKCepsilon in the heart, which are mitigated by endothelin receptor antagonist CPU0213.
Cheng YS; Dai DZ; Dai Y
Acta Pharmacol Sin; 2009 Aug; 30(8):1099-106. PubMed ID: 19597524
[TBL] [Abstract][Full Text] [Related]
20. CPU0213, a novel endothelin receptor antagonist, ameliorates septic renal lesion by suppressing ET system and NF-kappaB in rats.
He HB; Dai DZ; Dai Y
Acta Pharmacol Sin; 2006 Sep; 27(9):1213-21. PubMed ID: 16923343
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
